Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of nal-IRI + S-1 versus nal-IRI + 5-fluorouracil in second-line metastatic pancreatic cancer
2017-004675-31Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan in pancreatic cancer (PDAC) (2 arms), sponsored by Academic Medical Center. Started Oct 2019; status: active.
02
Drugs
irinotecan
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2017-004675-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004675-31.